Shire shares fall after reporting drop in sales of haemophilia drugs

The pharmaceutical company Shire has reported a drop in sales of haemophilia drugs, its biggest source of revenue since the $ 32bn acquisition of US firm Baxalta was completed in June.

The London-listed company’s third-quarter results disappointed the City. Shire shares closed down 2.6% at £45.28, the second day of falls, as investors also worried about the future pricing of haemophilia drugs in the US.

On Monday, Express Scripts, the largest manager of prescription drug plans for US companies, said it was looking at ways to manage the rising cost of haemophilia medicines.

Hillary Clinton is expected to tackle drug pricing if she wins the US presidential election. The Democratic candidate has repeatedly lambasted high pricing – describing that of EpiPen, drug firm Mylan’s emergency treatment of anaphylaxis, as “outrageous” and accusing entrepreneur Martin Shkreli of “price gouging” vital medicines.

Shire’s chief executive, Flemming Ørnskov, admitted that firms that managed prescription US drug plans wanted to “manage a number of categories more tightly” including haemophilia.

“We live in an environment, certainly during a presidential campaign, where price is in high focus,” he said.

“We can expect for all our categories, not just haemophilia, tighter management, but we have the programmes in place to make sure this does not affect our patients and has limited impact on our overall business. I remain incredibly confident about the outlook for haemophilia.”

Ørnskov said existing patients would not be forced to switch haemophilia medications as this would be considered too risky.

The Danish businessman was upbeat about Shire’s new drug for dry eye disease. Launched in August, Xiidra has already taken a 16% market share in the US. The eye drop is expected to generate annual sales of more than $ 1bn by 2020.

Shire said its integration of Illinois-based Baxalta, which specialises in treatments for rare blood conditions, cancer and immune system disorders, was ahead of schedule.

Sales of haemophilia medicines, also acquired from Baxalta, fell by 6% to $ 884m in the three months to 30 September, which Shire blamed on the timing of some large orders.

Overall, sales more than doubled to $ 3.3bn after the acquisition, but this was slightly lower than analysts had expected. Excluding Baxalta, revenues rose 12%.

Costs related to the takeover were also higher than Shire expected, partly because it has accelerated some factory closures in the US.

Shire is based in Dublin for tax purposes and run from Boston. As announced in the spring, it is pushing ahead with the closure of its Basingstoke office, where 270 people work.

The company wants to open an office in the Paddington, London, as its UK commercial base, so it can be “closer to the heart of life science communities”. There has been speculation that some staff may be moved to Dublin.

Shire shares fall after reporting drop in sales of haemophilia drugs

China Bribery Probe, Dismal Advair Product sales Depart Glaxo Shares Gasping

British drug giant GlaxoSmithkline (GSK) this morning slashed its earnings expectations for the year, citing currency fluctuations and deteriorating sales of its respiratory drug Advair, especially in light of moves in the U.S. by insurers unwilling to shell out for the a lot more costly brand title.

The price tag of Glaxo’s shares dipped by practically seven % soon after the business stunned investors with news that 2nd-quarter complete sales were down 13 % and there is a new twist to the company’s Chinese bribery scandal. Here’s a hyperlink to the whole Glaxo earnings report.

Glaxo executives admitted the “transition” of its respiratory portfolio was underway, but it’s not however enough to offset declining income of the as soon as well-known respiratory treatment Advair with product sales from its greatest franchise down practically twenty percent.  Eventually, the organization expects income of products like Breo, Anoro and Incruse “together with anticipated pipeline merchandise. . . to preserve respiratory leadership nicely into (the) up coming decade,” the organization mentioned in a statement this morning.

Advair product sales, the biggest contributor to its respiratory drug franchise, have been hit hard by the loss of patent safety and moves by pharmacy benefit managers who position the item in favored drug lists not to pay out for it like insurers have in the previous. The greatest PBM in the U.S., Express Scripts Express Scripts (ESRX) earlier this year excluded Advair among dozens of other medication from its nationwide formulary.

Meanwhile, investors are even now uneasy about the criminal probe by Chinese officials into allegations that GSK executives engaged in widespread bribery. GSK executives have been accused of illegally having to pay physicians, hospitals and other healthcare organizations in an effort to boost product sales of Glaxo products.

Just last month, reviews emerged of a intercourse tape involving a former Glaxo product sales manager in China that have extra to the drug maker’s woes in that nation.

And now this morning, investors are waking up to reports that the “Serious Fraud Office” in Britain are looking into Glaxo organization practices. The New York Instances, citing a particular person acquainted with the investigation, said the fraud workplace is searching at Glaxo enterprise practices in “multiple jurisdictions.”

Wondering how Obamacare will influence your prescriptions and well being care company sales? The Forbes eBook Within Obamacare: The Fix For America’s Ailing Health Care System answers that query and more. Accessible now at Amazon and Apple.

China Bribery Probe, Dismal Advair Product sales Depart Glaxo Shares Gasping

Arianna Huffington shares 3 guidelines from her guide "Thrive"

Seven years in the past, Arianna Huffington, editor-in-chief of the Huffington Post collapsed from exhaustion and burnout. This, she says, was the wake-up contact she required to make some constructive alterations in her life.

Ms Huffington has written ‘Thrive’ about the experiance and shared 3 tiny alterations everybody can make to keep away from a equivalent illness.

The initial tip: Get at least thirty minutes a lot more rest than you do now.

Second: At the finish of each and every day, pick a time to flip off all electronic devices and remove them from your bedroom.

Third: Drop anything at the finish of each and every day. This can be anything that is no longer serving you, be it a grudge, a resentment, or a undertaking.

Arianna Huffington shares 3 guidelines from her guide "Thrive"